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Abstract
Goals—To determine the impact of geography and patient characteristics on hepatitis C virus 
(HCV) genotype and subtype distribution in a large sample of patients under routine clinical care
Background—HCV genotype impacts disease course and response to treatment. Although 
several studies have reported genotype distribution within specific US populations, there are no 
comprehensive descriptions in large, geographically diverse cohorts.
Study—Using data from the Chronic Hepatitis Cohort Study, we present the distribution of HCV 
genotypes (GT) and subtypes (ST) among a racially diverse cohort of over 8000 HCV-infected 
patients from four large US health systems.
Results—Genotype distribution varied significantly by geographic and demographic factors. In 
age-adjusted analyses, African American patients had significantly higher prevalence of GT1 
(85%) than other racial categories, largely driven by a markedly higher proportion of GT1 subtype 
b (~34%) than in Asian/other (24%) and white (21%) patients. GT3 represented an increasing 
proportion of infections as birth decade progressed, from 4% in patients born before 1946 to 18% 
of those born after 1976. Within the cohort of “living/uncured” patients, highly elevated alanine 
aminotransferase (> 2 times the upper limit of normal) was significantly more common in GT3 
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patients, whereas Fibrosis-4 Index scores indicative of cirrhosis were most common in the 
combined group of GT4&6 patients.
Conclusion—Distribution of HCV genotypes and subtypes in the United States is more variable 
than suggested by previous national-level estimates and single-center studies. “Real-world” 
prevalence data may improve targeting of prevention, screening, and treatment efforts for hepatitis 
C.
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The hepatitis C virus (HCV) demonstrates remarkable genetic diversity, which complicates 
the development of effective treatments and potential vaccines. Even in the era of direct-
acting all-oral antiviral (DAA) therapies, treatment selection and effectiveness depend on 
viral genotype (GT) and subtype (ST). However, there have been few studies of HCV GT/ST 
distribution in the United States, and these have been confined to single health systems or 
limited by small sample sizes, large proportions of male patients, and incomplete description 
of subtypes.1–3 Furthermore, these studies also have not examined how various clinical 
factors, such as liver biochemistries, may vary across genotype and subtype. More 
comprehensive genotype and subtype data are necessary to guide HCV prevention, 
screening, and treatment efforts in the United States.
The Chronic Hepatitis Cohort Study (CHeCS) is a longitudinal study of hepatitis patients 
from four large US health systems, comprising a geographically and racially diverse cohort 
of over 10,000 HCV-infected patients. CHeCS has over 10 years’ of extensively annotated 
patient data, which permits us to report the real-world distribution of HCV GT/ST across 
site and patient characteristics, as well as to describe how clinical factors vary by GT/ST. In 
addition, we provide the genotype/subtype distribution of the living/uncured patients in our 
cohort—that is, patients who remain eligible for treatment with emerging DAA therapies.
METHODS
Study Population
CHeCS is an observational multicenter study that includes adult patients (18 y and above) 
from four large health systems. The study follows all guidelines of the US Department of 
Health and Human Services regarding the protection of human subjects; protocols are 
reviewed annually by the institutional review board at each study site—Geisinger Health 
System (GHS), Danville, PA; Henry Ford Health System (HFHS), Detroit, MI; Kaiser-
Permanente Hawai’i (KPHI), Honolulu, HI; and Kaiser-Permanente Northwest (KPNW), 
Portland, OR. Written informed consent was waived due to the de-identified nature of the 
data. CHeCS study methods have been previously described.4
Patient demographic information was collected at the time of entry into the cohort. Clinical 
data (including laboratory results for imputation of the Fibrosis-4 [FIB4] score5) were 
collected for the most recent encounter before December 2014. FIB4, a serum marker of 
hepatic fibrosis, was classified into one of three categories,6 using previously validated 
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cutoffs of ≤1.21 (for Metavir stages F0-2; “no to moderate fibrosis”), 1.21≥5.88 (F3-4; 
“advanced fibrosis”), and >5.88 (F4; cirrhosis). Charlson-Deyo comorbidity indices7 were 
imputed from electronic health record data for one year before each patient’s last encounter 
through December 31, 2014 to estimate their chronic disease burden. Detailed antiviral 
medication data were collected via chart abstraction. Treated patients were classified as 
having achieved sustained virological response (SVR) if laboratory results ≥12 weeks post-
therapy showed undetectable viral loads; those who did not achieve SVR were classified as 
“treatment failure.” Death data were collected through various resources including the 
National Death Index and Social Security Death Index.
HCV genotype was collected from electronic capture of laboratory results, supplemented 
with chart review. Patients with more than one or inconsistent genotypes in the medical 
record were classified by the genotype reported first. For GT1 and 2, subtypes were 
classified as “a,” “b,” or “other” ([o], >1 subtype or not reported in the medical record). 
Because of low frequency, subtypes for other genotypes were not reported. The sole patient 
with GT5 was excluded from analyses.
Statistical Analyses
Descriptive summary statistics are presented as counts and percentages (row percentages for 
Tables 1A and 2A, column percentages for Tables 1B and 2B). Chi-squared tests were used 
to test the population difference between genotyped and nongenotyped patients, and among 
GT/ST categories. Bar charts were used to illustrate proportional distribution of GT/ST by 
patient demographic factors and proportional frequency of clinical factors across GT/ST.
We used generalized logit models to determine whether GT/ST distributions differed by 
geography (clinical site) and patient characteristics (sex, race, and birth decade). 
Multivariable analyses were performed to adjust for possible confounding.4 Pairwise GT/ST 
comparisons were performed if there was overall significance at the criteria of 0.05. 
Adjusted probabilities (percent) of each GT/ST were estimated from these models using the 
marginal standardization method.8,9 Briefly, this method calculates the estimated 
probabilities separately for each level of variables in the model, and then combined as a 
weighted average for each level of variable of interest. 95% confidence intervals (CI) were 
estimated using the Bootstrap approach.10 Differences between two groups are significant if 
the CIs do not overlap. A similar analytic approach was used to study the distribution of 
clinical factors across GT/ST, adjusting for patient characteristics (such as race and birth 
year).
RESULTS
HCV genotype was available for 8140 (75%) of the 10,738 HCV-infected patients in our 
cohort, after exclusion of the sole patient with genotype 5. There were a number of 
significant differences between patients with and without genotype data (Supplemental 
Table 1, Supplemental Digital Content 1, http://links.lww.com/JCG/A351). As genotyping is 
often performed before initiation of antiviral therapy, patients with HCV genotyping were 
more likely to receive HCV treatment than those without genotyping (46% vs. 23%). 
Patients with available data were also significantly more likely to have private insurance and 
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to have fewer comorbid conditions. Notably, markers of the severity of liver disease [alanine 
aminotransferase (ALT) levels and FIB4 indices] did not differ significantly between 
patients with and without genotype data. Patients co-infected with either human 
immunodeficiency virus or hepatitis B virus represented only 1% to 3% of all genotyped 
patients. Because rates did not differ significantly by GT/ST, these patients were included in 
all analyses.
Univariate Analyses: All Genotyped Patients
Table 1 and Figure 1 present the distribution of GT/ST across patient characteristics for all 
genotyped patients. GT1 was most common (75.4%), followed by 2 (12.6%) and 3 (10.2%); 
GT4 (1.5%) and 6 (0.3%) were much less prevalent.
However, chi-squared tests showed significant differences in the distribution of GT/ST 
across all demographic variables, as well as by site (P < 0.01, except sex; P = 0.022). For 
example, the proportion of patients with GT1 ranged from 65% (KPNW, Portland, OR) to 
84% (HFHS, Detroit, MI). Black/African American patients had significantly higher 
prevalence of GT1 (over 93%) than other racial categories; this was largely driven by a 
markedly larger proportion of GT1b than in Asian/other and white patients. Likewise, as 
birth year increased (age decreased), the proportion of GT1b also decreased, from 41% in 
patients born before 1946 to <10% in patients born after 1975. This trend was reflected by 
changes in the proportion of GT3, which became more common as age decreased, 
representing only 3% of infections in the oldest patients but 18% of infections among the 
youngest patients.
Multivariate Analyses and Adjusted Probability: All Genotyped Patients
Birth decade, patient race, and study site were all independently associated with genotype 
distribution (P < 0.01). Although genotype distribution varied significantly by sex in the 
univariate analysis, the significant association did not persist in the multivariate analysis. 
Figures 2–4 display the adjusted probabilities for each GT/ST across CHeCS sites, patient 
race, and birth decade, respectively. 95% CIs are included to permit comparisons of 
significant differences within categories and between GT/ST.
Sites/Geography
After adjustment for differences in the racial and age makeup of each CHeCS health system, 
the GT/ST distribution remained significantly different across sites (Fig. 2). As in the 
univariate analysis, the largest proportion of infections were GT1a (41.1% to 48.6%). 
However, HFHS (Detroit, MI) and KPHI (Honolulu, HI) had significantly larger proportions 
(4.8% to 7.5% higher) of GT1a than GHS and KPNW (Dansville, PA and Portland OR, 
respectively). GT3 demonstrated a similar geographic pattern (higher proportions at HFHS 
and KPHI; lower proportions at GHS and KPNW).
HFHS demonstrated a significantly higher adjusted probability of GT1b (27.6% vs. 20.1% 
to 22.1%) and GT4 (2.5% vs. 0.4% to 1.5%) compared with other sites; adjusted 
probabilities of 2b and 2o were significantly lower (5.0% vs. 8.3% to 11.5%, and 1.0% vs. 
3.2% to 6.4%, respectively). KPNW demonstrated a roughly 1.5- to 2-fold higher 
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probability of GT2b (11.5%) and 2o (6.4%) than other sites, and a 4- to 8-fold higher 
probability of GT6 (0.8% vs. 0.1% to 0.2%).
Race
After adjustment for differences in the age distribution of patients in each racial category, 
GT/ST distribution remained significantly different across patient race (Fig. 3). Even after 
age-adjustment, black/African American patients demonstrated 8% to 12% higher adjusted 
probability of GT1a (51.3% vs. 39.2% to 43.3%) and 10% to 13% higher probability of 
GT1b (33.6% vs. 20.5% to 23.6%) than Asian/other or white patients; this was reflected in 
significantly lower probabilities of GT2b, 2o, 3, and 4 than other racial groups.
GT6 was confined exclusively to Asian/other patients (3.1% vs. 0%). Asian/other patients 
also demonstrated the highest adjusted probability of GT4 (4.9% vs. 0.4% to 1.6%), and less 
overall variability in GT/ST distribution than other racial groups. White patients 
demonstrated the highest adjusted probabilities of GT2b (9.8%) and 3 (13.1%).
Birth Decade
After adjustment for differences in the racial and geographic distribution of patients in our 
sample, the distribution of GT/ST remained significantly different across birth decades (Fig. 
4). As in the unadjusted analyses, GT1a represented the largest proportion of infections 
across all birth decades, except for patients born before 1946, who were equally likely to 
have GT1b. The adjusted probability of 1b infections decreased steadily and significantly 
across birth decades, from 35% in patients born before 1946 to <11% in patients born after 
1975. GT2b and 2o demonstrated a similar but nonsignificant pattern, although these 
differences were significant when comparing the oldest (< 1946) and youngest (≥1976) 
patients.
The adjusted probabilities of GT1a, 3, and 4 increased across each birth decade, from oldest 
to youngest patients. Proportion of GT1a rose from 32.7% to 55.3%, a 1.7-fold increase, 
while the proportion of GT4 rose from 1.4% to 4%, a roughly 3-fold increase. GT3 
demonstrated the largest proportional increase, from 3.6% in patients born before 1946 to 
17.8% in patients born after 1976, a 5-fold increase. Among patients born after 1976, GT1a 
and 3 were the most common, representing almost three-quarters of all infections among the 
youngest patients.
Notably, we observed significant differences between the two decades comprised by the 
“Baby Boomer” birth cohort, a group that is often analyzed as a single unit. Older patients in 
this cohort (born 1946 to 1955) were significantly more likely than their younger 
counterparts (born 1956 to 1965) to have GT1b (adjusted probability of 27% vs. 19.5%). 
Younger cohort members were significantly more likely to have GT1a (46.8% vs. 43.2%) 
and GT3 (12.9% vs. 7.7%) than older cohort members.
Univariate Analysis: Living/Uncured Patients
Unadjusted treatment receipt and vital status across GT/ST are described in Table 1 and 
Figure 1. Because of the necessity of using complex time-to-event analyses to determine the 
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impact of age and other confounders upon these outcomes, multivariate analyses were not 
performed. The cohort of 5138 patients who were still living and had not achieved SVR as 
of December 2014 is described in Table 2. In general, distribution of genotypes across 
“living/uncured” patients was similar to that of the “all genotyped” patients, with the 
exception of a slight increase (2% to 7%) in the proportion of GT1a patients across all 
demographic characteristics. In unadjusted analyses, clinical factors varied across GT/ST 
(Fig. 5); ALT, FIB4 were selected for further analyses.
Multivariate Analysis: Living/Uncured Patients
Although the relationship between GT/ST and comorbidity indices did not remain 
significant after adjustment (Fig. 5), the adjusted probability of ALT and FIB4 varied 
significantly by genotype (Fig. 6). Among living/uncured patients with available ALT data 
(n = 3715), roughly half (49.0% to 63.6%) had “normal” ALT levels. GT3 patients 
demonstrated the highest probability of highly elevated upper limit of normal (≥2*ULN) 
ALT (21.1% vs. 11.6% to 14.1%). This difference was significant for GT1a and 1b, and 
approached significance for GT1o and 2; GT4&6 displays a wide CI due to small sample 
size (n = 12). GT3 patients were also the least likely to have “normal” ALT (49.0% vs. 
53.3% to 63.6%, significantly lower than 1a, 1b, and 2). GT2 patients were more likely to 
have normal ALT and less likely to have “elevated” ALT (normal <2*ULN) compared with 
other patients with other GT/STs; this difference was significant for GT1a and 3.
We have previously shown that a FIB4 cutoff of >5.88 reliably predicts cirrhosis in this 
cohort.6 Among living/uncured patients with available FIB4 data (n = 3173), GT4&6 
patients demonstrated the largest proportion of patients with FIB4-defined cirrhosis; even 
with a wide CI, this proportion was significantly larger than that of other GT/STs except 
GT3 and 1b. GT3 patients also demonstrated a high probability of FIB4-indicated cirrhosis 
(19%); this was significantly higher than GT1a and 2. The majority of patients of all 
genotypes (~55% to 67%, except GT4&6) had FIB4 values of 1.21 to 5.88, suggesting that 
moderate-to-severe fibrosis is common among the cohort of patients who remain candidates 
for DAA therapy.
DISCUSSION
In this cohort of over 10,000 US patients, we observed marked variation in genotype and 
subtype distribution across site-level and patient-level characteristics. Results from previous 
studies confined to single-state populations (California1 and Texas3) have suggested that 
genotype distribution varies by both geography and demographics, although it is not possible 
to directly compare these cohorts. These studies are also limited by a lack of clinical data or 
restricted to univariate analyses. We applied extensive medical record data from four large 
health systems to both univariate and multivariate analyses to generate a comprehensive 
picture of both genotype/subtype distribution and associated clinical characteristics.
Although “Baby Boomer” HCV-infected patients are often analyzed collectively, our data 
suggest that this is not a homogenous group. In both unadjusted and adjusted analyses, 
patients born in the second decade of this cohort (1956 to 1965) had significantly lower 
proportions of GT1b and higher proportions of GT1a and 3 than their older counterparts 
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(born from 1946 to 1955); in general, younger cohort members resembled patients born the 
following decade (from 1966 to 1975, no significant differences in proportions between 
these two birth decades) more than they resembled those born from 1946 to 1955.
Consistent with these findings, as birth decades progressed, the proportions of GT1b 
significantly decreased while the proportions of GT1a and 3 increased; among patients born 
1976 and after, the proportion of GT3 infections was five times higher than that among 
patients born before 1946. This finding is consistent with a large, laboratory-based study that 
found GT3 patients to be significantly younger than those with other genotypes.11 This 
genotype shift likely represents changes in patterns of HCV exposure over time in the 
United States—from medical exposure (associated with GT1b) to injection drug use 
(frequently associated with GT1a and 3).12
This increasing proportion of GT3 infection among younger patients has important 
epidemiological and clinical considerations.13 In analyses adjusted for differences in race 
and age, we found significant differences in ALT values between genotypes. Among our 
living/uncured patient cohort, GT3 patients had the highest rates of “highly elevated” ALT; 
over 21% of GT3 patients had ALT values >2 times the upper limit of normal. We are not 
aware that this observation has been previously reported in a primarily HCV mono-infected 
cohort. GT3 is associated with aggressive progression of fibrosis and cirrhosis,14 likely 
contributing to the increased risk of hepatocellular carcinoma (HCC) that we and others have 
reported in GT3 patients.15,16 Although high rates of hepatic steatosis and diabetes have 
been implicated in this rapid progression of liver disease, a recent in vitro study found that 
GT3 also provokes a uniquely inflammatory hepatic immune response; the elevated ALT 
values we observed in GT3 patients may reflect increased necroinflammatory activity.17 
Additional research exploring the implications of this observation is warranted.
Likewise, there is a significant burden of fibrosis among our entire cohort of living/uncured 
patients; roughly 70% to 80% of living/uncured patients have FIB4 indices >1.21 (at least 
moderate fibrosis). Although direct comparisons are not possible (all FIB4 patients have 
ALT values but not viceversa), the majority of living/uncured patients demonstrated 
“normal” ALT values, but only 20% to 30% of patients demonstrated FIB4 values consistent 
with “no to mild” fibrosis (< 1.21).6 In fact, over 25% of GT4&6 patients and 19% of GT3 
patients demonstrated FIB4-indicated cirrhosis—despite the relatively younger age profile of 
the latter. Clinical awareness of the variability of indicators of the severity of liver 
inflammation and fibrosis as a function of GT/ST, even after controlling for age and race, 
may influence both screening and treatment decisions.
GT/ST distribution varied significantly by race in both univariate analyses as well as 
multivariate analyses that adjusted for differences in age distribution across the 3 racial 
categories used. African American patients overwhelmingly demonstrated infection with 
GT1—most notably an adjusted probability of 1b (33%) roughly 1.5 times that of white 
(21%) and Asian (24%) patients. We note that these rates were consistent between the full 
cohort and the living/uncured cohort. A similarly high rate of 1b in black/African American 
patients was shown in a recent study from a single health center in Texas,3 a region not 
represented in our sample. To our knowledge, an epidemiological explanation for the 
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dramatic over-representation of this subtype within African Americans has not been 
reported. However, given that African Americans have been less likely to receive interferon-
based HCV treatment—for reasons that include higher rates of comorbidities/
contraindications and lower response rates compared with other racial/ethnic groups18–21—
the efficacy of newer regimens in treating this subtype22 may address some of the disparities 
in treatment and long-term outcomes observed in these patients. We also observed that GT6 
infection was confined almost entirely to Asian patients. Given the relatively higher 
prevalence of GT6 in China and other parts of Asia,23 it is likely that the GT6 patients in our 
cohort were infected before arrival in the United States.
Recent worldwide HCV genotype distribution estimates considered the US or North 
America as a single unit.23,24 However, our data show that genotype distribution varies 
considerably across study sites, even after adjusting for differences in the age and racial 
makeup of each cohort. Although previous US-based studies have demonstrated regional 
differences in genotype distribution, variation across regions was lower (< 10%),11 and did 
not control for differences in age and racial makeup of each region. Other studies of 
genotype distribution in the US were limited by small sample sizes2,25 or were confined to a 
single health system1 or geographic region.25 Although our results are generally consistent 
with these reports, our analysis extends these findings by including a broader spectrum of 
genotypes/subtypes and their association with clinical characteristics; we also performed 
multivariate analyses that allowed us to adjust these analyses for race, birth decade, and 
clinical site. A considerable strength of this analysis is that CHeCS comprises sites spanning 
the continental US as well as Hawai’i. Notably, relative proximity did not appear to 
influence genotype distribution; in general, adjusted probabilities for each GT/ST were most 
similar between HFHS (Detroit, MI) and KPHI (Honolulu, HI). Although this study is not 
designed to investigate factors related to the local epidemiology of HCV, our data 
demonstrate that GT distribution in a single community or health system may not be 
generalizable to the US as a whole.
We acknowledge that there is some question regarding the future clinical relevance of HCV 
genotype as pangenotypic treatments are anticipated to become the standard of care. 
Nevertheless in 2017, genotype—coupled with previous treatment experience and degree of 
fibrosis—remains an important parameter when determining treatment. We believe that a 
comprehensive illustration of pre-DAA era HCV genotype distribution in the US, 
particularly among the pool of HCV patients who remain candidates for DAA treatments, 
remains important to the clinician. As the more easily treated genotypes become less 
common, the proportion of “difficult to treat” genotypes will increase; as a result, genotype-
specific regimens will likely remain part of the clinician’s repertoire.
Likewise, treatment remains but one clinical indication for genotype identification. For 
example, genotype may be used to determine whether a “cured” patient has been re-infected 
or is experiencing viral reemergence. As we and others have shown, clinical outcome and 
hepatocellular cancer risk varies by genotype; for example, we have previously shown that 
genotype 3 is associated with increased risk of HCC compared with other genotypes.26 Our 
data show demographic shifts in genotype frequency (from 1b among older patients to 3 
among younger patients). The increasing proportion of genotype 3 among younger 
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individuals—presumably with shorter disease duration and subsequently less fibrosis—
should heighten public awareness and reinforce efforts toward earlier treatment. Left 
untreated, these patients are likely to progress rapidly to advanced fibrosis and an increased 
risk for HCC. Differences in long-term outcomes, even among patients who achieve SVR, 
may also vary by genotype.
Another limitation of our study is a lack of data regarding source of infection. A large subset 
of CHeCS patients responded to a survey that included questions about how they acquired 
HCV; however, the majority of patients did not know or declined to answer this question 
(data not shown). This lack of data regarding the source of infection limits our ability to 
investigate underlying reasons for the observed differences in GT/ST distribution as well as 
our ability to estimate duration of infection. The cross-sectional analysis also limits our 
ability to draw causal inferences, and some small cell counts, particularly within our living/
uncured cohort, reduce statistical power to observe some significant differences.
The timeline of our data collection—through December 2014—means that we have little 
data regarding patients who have been treated since the widespread implementation of DAA 
treatment regimens. However, roughly one-quarter to one-third of all living patients in this 
cohort have previously failed treatment, further increasing their risk for cirrhosis and HCC.
15
 Although proportions varied by genotype, our entire cohort of living/uncured patients 
demonstrate high levels of moderate-to-severe fibrosis and cirrhosis, as indicated by FIB4 
scores. Although a number of DAA regimens are now available, access to these therapies has 
been limited, and there remains a large pool of patients who may be considered priority 
candidates for therapy.27
In conclusion, the overall distribution of HCV genotypes and subtypes in the United States 
reported in this analysis largely reflects previous estimates, but these estimates paint an 
incomplete picture. On the basis of comprehensive data from over 8000 HCV-infected 
patients from four large health systems, we show that genotype distribution varies 
significantly by geography and demographics, with genotype-distinct clinical features, 
creating unique subpopulations. The current detailed characterization demonstrates wide 
variation in the proportion of HCV genotypes within a large real-world population and may 
inform the development and optimization of US HCV eradication efforts.
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FIGURE 1. 
All genotyped patients (N = 8140). A, Unadjusted proportional distribution of HCV GT/ST 
by site and patient-level characteristics. B, Unadjusted proportional distribution of treatment 
and vital status by GT/ST. GHS indicates Geisinger Health System; GT, genotype; HCV, 
hepatitis C virus; HFHS, Henry Ford Health System; KPHI, Kaiser-Permanente Hawai’I; 
KPNW, Kaiser-Permanente Northwest; SVR, sustained virological response; ST, subtype.
Gordon et al. Page 12
J Clin Gastroenterol. Author manuscript; available in PMC 2019 January 21.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
FIGURE 2. 
All genotyped patients (N = 8140), adjusted probability of GT/ST by CHeCS site. Category 
(site) percentages sum to 100. GHS indicates Geisinger Health System; GT, genotype; 
HFHS, Henry Ford Health System; KPHI, Kaiser-Permanente Hawai’I; KPNW, Kaiser-
Permanente Northwest; ST, subtype.
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FIGURE 3. 
All genotyped patients (N = 8140), adjusted probability of GT/ST by race. Category (race) 
percentages sum to 100. GT indicates genotype; ST, subtype.
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FIGURE 4. 
All genotyped patients (N = 8140), adjusted probability of GT/ST by birth decade. Category 
(birth decade) percentages sum to 100. GT indicates genotype; ST, subtype.
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FIGURE 5. 
Living/uncured patients (N = 5138), unadjusted proportional distribution of select clinical 
factors across GT/ST. A, ALT category at most recent encounter, subset of living/uncured 
patients with available data (n = 3715). B, FIB4 category at most recent encounter, subset of 
living/uncured patients with available data (n = 3173). C, Charlson/Deyo comorbidity index 
as of most recent encounter, all living/uncured patients (N = 5138). ALT indicates alanine 
aminotransferase; FIB4, Fibrosis-4; GT, genotype; ST, subtype; ULN, upper limit of normal.
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FIGURE 6. 
Living/uncured patients: adjusted probability of (N = 5138) ALT (A) and FIB4 (N = 3173) 
(B) by GT/ST. Genotype/subtype percentages sum to 100. ALT indicates alanine 
aminotransferase; FIB4, Fibrosis-4; GT, genotype; ST, subtype.
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